Jubilant Pharmova Ltd Stock Price Today (NSE: JUBLPHARMA)
Fundamental Score
Jubilant Pharmova Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jubilant Pharmova Ltd share price today is ₹994.00, up +1.43% on NSE/BSE as of 17 June 2026. Jubilant Pharmova Ltd (JUBLPHARMA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹17.63K (Cr). The 52-week high for JUBLPHARMA share price is ₹1248.00 and the 52-week low is ₹786.05. At a P/E ratio of 35.47x, JUBLPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 9.55% and a debt-to-equity ratio of 0.44.
Jubilant Pharmova Ltd Share Price Chart — NSE/BSE Historical Performance
Jubilant Pharmova Ltd share price chart: 3.85% return over the past month. 52-week high ₹1248.00, 52-week low ₹786.05.
Jubilant Pharmova Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹966.50 | ₹984.00 | ₹959.00 | ₹975.05 | 91.43K (Cr) | |
| ₹983.00 | ₹997.75 | ₹968.00 | ₹987.55 | 1.04L (Cr) | |
| ₹993.00 | ₹1002.65 | ₹978.55 | ₹995.00 | 1.50L (Cr) | |
| ₹985.95 | ₹993.95 | ₹977.45 | ₹991.75 | 60.22K (Cr) | |
| ₹1002.70 | ₹1002.75 | ₹983.35 | ₹985.20 | 1.16L (Cr) | |
| ₹1006.45 | ₹1014.90 | ₹955.25 | ₹1007.25 | 3.73L (Cr) | |
| ₹1014.50 | ₹1025.00 | ₹988.00 | ₹1006.35 | 5.32L (Cr) | |
| ₹1022.00 | ₹1023.30 | ₹999.30 | ₹1011.65 | 90.79K (Cr) | |
| ₹1006.00 | ₹1020.50 | ₹1002.40 | ₹1014.20 | 77.99K (Cr) | |
| ₹1009.75 | ₹1030.00 | ₹999.00 | ₹1010.95 | 2.67L (Cr) |
Jubilant Pharmova Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹983.00 | ₹997.75 | ₹959.00 | ₹975.05 | -0.81% | |
| ₹931.05 | ₹1031.70 | ₹927.25 | ₹995.00 | +6.87% | |
| ₹821.50 | ₹959.35 | ₹800.05 | ₹926.60 | +12.79% | |
| ₹828.60 | ₹886.30 | ₹786.05 | ₹816.45 | -1.47% | |
| ₹959.10 | ₹998.35 | ₹847.20 | ₹866.30 | -9.68% | |
| ₹1068.00 | ₹1107.80 | ₹926.90 | ₹981.90 | -8.06% | |
| ₹1089.70 | ₹1118.50 | ₹1011.00 | ₹1073.30 | -1.51% | |
| ₹1105.00 | ₹1183.00 | ₹1045.50 | ₹1089.70 | -1.38% | |
| ₹1078.90 | ₹1184.80 | ₹1033.00 | ₹1101.00 | +2.05% | |
| ₹1023.10 | ₹1148.90 | ₹1016.50 | ₹1079.40 | +5.50% | |
| ₹1180.00 | ₹1194.30 | ₹1012.20 | ₹1023.10 | -13.30% | |
| ₹1210.60 | ₹1248.00 | ₹1093.00 | ₹1194.10 | -1.36% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Expensive CDMO/Radiopharma play needing flawless execution to justify valuation.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Jubilant Pharmova's trading window closed on April 1, 2026, ahead of FY26 results. Q3 FY26 results, released in February, showed a 17% YoY revenue increase to Cr, but PAT declined 17% to due to exceptional losses.
CORE STORY (THE REAL GAME)
- CDMO growth story intact
- Radiopharma expansion on track
- Generics showing signs of improvement
- Positive surprise in FY26 results
- New CDMO contracts
- Successful Ruby-Fill rollout in Europe and Asia
- High valuation vs. industry P/E
- Margin pressure in key segments
- Dependence on US market (75% of revenue)
FII decreased holdings by 0.84%, DII increased holdings by 1.01%.
Indian pharma exports are rising, but US tariff threats remain a headwind.
Yes - Free Cash Flow 5Y: ₹1420.65 Cr
Expect continued growth in CDMO and radiopharma segments. Monitor margin trends and US market dependence.
Primary Thesis Risk
Execution risk in CDMO and radiopharma expansion could derail growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Jubilant Pharmova Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jubilant Pharmova Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JUBLPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (16.66%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Cash Generation (₹1420.65 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 27.09%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
5 factors identified
Below-Average Return on Equity (9.55%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.54%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (3.90% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-9.56% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-9.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Jubilant Pharmova Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Jubilant Pharmova Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Jubilant Pharmova LtdJubilant Pharmo...Selected✓ JUBLPHARMA • 530019 | 33.4/100 | ₹994.00₹994 | ₹17630.07₹17630.07 | 35.47Average 35.5 Average | 9.55%Poor 9.55% Poor | 9.54%Poor 9.54% Poor | 0.44Excellent 0.4 Excellent | -9.56%Poor -9.56% Poor | 3.90%Average 3.90% Average | 0.45% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Jubilant Pharmova Ltd PE Ratio History
Historical price-to-earnings ratio for JUBLPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹52.85 | ₹1073.30 | 20.3x |
| FY 2024 | ₹4.86 | ₹1105.20 | 227.4x |
| FY 2022 | ₹26.00 | ₹374.75 | 14.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Jubilant Pharmova Ltd Dividend History
Annual cash dividends paid by JUBLPHARMA — dividend yield 0.45%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹79.60 Cr |
| FY 2024 | ₹79.80 Cr |
| FY 2023 | ₹80.10 Cr |
| FY 2022 | ₹80.05 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Jubilant Pharmova Ltd Quarterly Performance
Latest quarterly metrics for JUBLPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.22%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
9.81%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
3.90%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-9.56%
Compounded annual net profit growth over 5 years
Jubilant Pharmova Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for JUBLPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Jubilant Pharmova Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Jubilant Pharmova Ltd (JUBLPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Jubilant Pharmova Ltd
About JUBLPHARMA (Jubilant Pharmova Ltd)
Jubilant Pharmova Ltd is a global pharmaceutical powerhouse, deeply entrenched in the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products... and services. From its Indian roots, the company has expanded its footprint across the Americas, Europe, and beyond, becoming a key player in multiple therapeutic areas. Jubilant Pharmova's comprehensive business model spans the entire pharmaceutical value chain, encompassing research and development, active pharmaceutical ingredient (API) production, finished dosage formulation manufacturing, and contract manufacturing services. This vertically integrated approach allows for greater control over quality, cost, and supply chain efficiencies, positioning the company as a reliable partner for healthcare providers and pharmaceutical companies worldwide. The company’s operational structure is divided into strategic business segments, each focusing on specific areas of pharmaceutical expertise. These divisions range from the development and production of life-saving radiopharmaceuticals used in medical imaging and therapy, to allergy immunotherapy products designed to improve the lives of patients suffering from allergic conditions. Jubilant Pharmova also boasts a robust contract development and manufacturing organization (CDMO) specializing in sterile injectables, catering to the growing demand for specialized drug delivery systems. Furthermore, the company maintains a generics division focused on providing affordable medications, a contract research, development and manufacturing organization (CRDMO) division, and a proprietary novel drugs segment, highlighting its commitment to innovation and the development of new treatment modalities. Jubilant Pharmova’s unwavering commitment to quality, regulatory compliance, and innovation underpins its success in the global pharmaceutical landscape. The company invests heavily in research and development, constantly striving to improve existing products and develop novel therapies to address unmet medical needs. Its state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the safety and efficacy of its products. By fostering a culture of continuous improvement and a patient-centric approach, Jubilant Pharmova continues to solidify its position as a leading pharmaceutical company dedicated to improving global healthcare outcomes.
Company Details
Key Leadership
Corporate Events
JUBLPHARMA Share Price: Frequently Asked Questions
What is the current share price of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd (JUBLPHARMA) trades at ₹994.00 on NSE and BSE. Market cap ₹17.63K (Cr). Educational data only.
What is the P/E ratio of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a P/E of 35.47x vs industry average 31.77x.
What is the Bull Run score for Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has a Bull Run score of 33.4/100 based on 25+ financial parameters.
Does Jubilant Pharmova Ltd pay dividends?
Jubilant Pharmova Ltd has a dividend yield of 0.45%. Past dividends don't guarantee future payments.
What is the ROE of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has ROE of 9.55%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd has debt-to-equity of 0.44.
Is Jubilant Pharmova Ltd a good investment?
Bull Run gives Jubilant Pharmova Ltd a score of 33.4/100. This is not investment advice — consult a SEBI-registered advisor.